
Elisa Frisaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood, 2003, 101, 1962-1969.	1.4	139
2	Pain and the context. Nature Reviews Rheumatology, 2014, 10, 348-355.	8.0	92
3	Placebo and Nocebo Effects: A Complex Interplay Between Psychological Factors and Neurochemical Networks. American Journal of Clinical Hypnosis, 2015, 57, 267-284.	0.6	60
4	Teaching neurons to respond to placebos. Journal of Physiology, 2016, 594, 5647-5660.	2.9	60
5	Why We should Assess Patients' Expectations in Clinical Trials. Pain and Therapy, 2017, 6, 107-110.	3.2	47
6	Role of explicit verbal information in conditioned analgesia. European Journal of Pain, 2015, 19, 546-553.	2.8	42
7	Characterization of the thalamic–subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients. Cortex, 2014, 60, 3-9.	2.4	32
8	Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders. Muscle and Nerve, 2017, 56, 358-367.	2.2	32
9	The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning. Movement Disorders, 2017, 32, 1474-1478.	3.9	27
10	Nocebo and the contribution of psychosocial factors to the generation of pain. Journal of Neural Transmission, 2020, 127, 687-696.	2.8	26
11	Thirty Years of Neuroscientific Investigation of Placebo and Nocebo: The Interesting, the Good, and the Bad. Annual Review of Pharmacology and Toxicology, 2022, 62, 323-340.	9.4	21
12	The Effects of Placebos and Nocebos on Physical Performance. Handbook of Experimental Pharmacology, 2014, 225, 149-157.	1.8	18
13	How do placebos work?. Högre Utbildning, 2018, 9, 1533370.	3.0	17
14	Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial. Neurological Sciences, 2021, 42, 5045-5053.	1.9	16
15	Prognostic Values of Soluble CD30 and CD30 Gene Polymorphisms in Heart Transplantation. Transplantation, 2006, 81, 1153-1156.	1.0	14
16	Creating placebo responders and nonresponders in the laboratory: boons and banes. Pain Management, 2014, 4, 165-167.	1.5	14
17	Placebo responders and nonresponders: what's new?. Pain Management, 2018, 8, 405-408.	1.5	9
18	The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A metaâ€analysis. Muscle and Nerve, 2019, 59, 671-678.	2.2	7

Elisa Frisaldi

#	Article	IF	CITATIONS
19	Nonlinear analysis of electroencephalogram in frontotemporal lobar degeneration. NeuroReport, 2014, 25, 496-500.	1.2	6
20	Verbal communication about drug dosage balances drug reduction in Parkinson's disease: Behavioral and electrophysiological evidences. Parkinsonism and Related Disorders, 2019, 65, 184-189.	2.2	6
21	Identification of a new HLA-DRB1 allele in three members of an Italian family. Tissue Antigens, 2004, 64, 210-212.	1.0	4
22	The subthalamic nucleus and the placebo effect in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 180, 433-444.	1.8	4
23	Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques+. Tissue Antigens, 2006, 67, 427-429.	1.0	3
24	The need to investigate nocebo effects in more detail. World Psychiatry, 2019, 18, 227-228.	10.4	3
25	Neurochemistry of Placebo Analgesia. , 2013, , 9-14.		2
26	Placebo effects: the need for a new perspective and conceptualization. Expert Review of Clinical Pharmacology, 2018, 11, 543-544.	3.1	1
27	Placebo and nocebo responses in Parkinson's disease. , 2020, , 527-541.		1
28	What is the role of placebo in neurotherapeutics?. Expert Review of Neurotherapeutics, 2021, , .	2.8	1
29	Placebo Effect. , 2022, , 731-738.		0